AmeriFlex Group’s Lineage Cell Therapeutics LCTX Stock Holding History

AmeriFlex Group’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,200	Closed	-$994	–	1188
2025 Q1	$994	Hold	2,200	–	–	﹤0.01%	1201
2024 Q4	$1.32K	Buy	+2,200	New	+$1.61K	﹤0.01%	1086

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return

Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

AmeriFlex Group's LCTX Position: Q2 2025 in Review

AmeriFlex Group sold out of Lineage Cell Therapeutics (LCTX) in Q2 2025, closing a stake of 2,200 shares — an estimated $994 sold.

AmeriFlex Group first reported a position in LCTX in Q4 2024 and held it in 2 quarters. The position peaked at $1.32K in Q4 2024. 129 funds tracked by Wall St. Rank hold LCTX as of Q2 2025.

AmeriFlex Group reported no remaining Lineage Cell Therapeutics position as of Q2 2025 after selling out during the quarter.
AmeriFlex Group sold 2,200 Lineage Cell Therapeutics shares in Q2 2025, an estimated $994.
AmeriFlex Group first reported a position in Lineage Cell Therapeutics in Q4 2024 and held it in 2 quarters.
AmeriFlex Group's Lineage Cell Therapeutics position peaked at $1.32K in Q4 2024.
129 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2025.

Based on AmeriFlex Group's 13F filing for Q2 2025, filed 21 Jul 2025.